{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:00:09Z","timestamp":1793386809012,"version":"4.5.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>We provide the results of the first interventional study of cytomegalovirus (CMV)-specific immune monitoring to direct the length of antiviral prophylaxis in lung transplantation (LTx).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>Patients (n = 118) at risk of CMV infection were randomized 1:2 to either 5 months or variable length valganciclovir prophylaxis (5\u201311 mo post-LTx), as determined by the QuantiFERON (QFN)-CMV assay. Patients with a negative QFN-CMV assay (&lt;\u20090.2 IU\/mL) received prolonged valganciclovir prophylaxis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>The primary endpoint that was the incidence of CMV infection in the lung allograft within 18 months of LTx was significantly reduced in the QFN-CMV directed arm (37% versus 58%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.03). Secondary endpoints that included blood viremia, acute rejection, and chronic lung allograft dysfunction did not differ between the 2 arms. Of the 80\/118 patients who ceased antiviral prophylaxis at 5 months, the incidence of viremia (&gt;\u2009600 copies\/mL) within the blood was significantly reduced in patients with a positive QFN-CMV assay compared with those without protective immunity (13% versus 67%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.0003), as was the incidence of severe viremia (&gt;\u200910\u2009000 copies\/mL) (3% versus 50%, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt;\u20090.001). Ceasing antiviral prophylaxis at 11 months in patients with a negative assay was associated with a 25% incidence of late CMV viremia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Cytomegalovirus immune monitoring allows an individualized approach to CMV prophylaxis and reduces late CMV infection within the lung allograft.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000002454","type":"journal-article","created":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T07:06:42Z","timestamp":1538204802000},"page":"1005-1013","source":"Crossref","is-referenced-by-count":88,"title":["A Randomized Study of Quantiferon CMV-directed Versus Fixed-duration Valganciclovir Prophylaxis to Reduce Late CMV After Lung Transplantation"],"prefix":"10.1097","volume":"103","author":[{"given":"Glen P.","family":"Westall","sequence":"first","affiliation":[{"name":"Lung Transplant Service, Alfred Health and Monash University, Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Cristiano","sequence":"additional","affiliation":[{"name":"Lung Transplant Service, Alfred Health and Monash University, Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwyn J.","family":"Levvey","sequence":"additional","affiliation":[{"name":"Lung Transplant Service, Alfred Health and Monash University, Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Whitford","sequence":"additional","affiliation":[{"name":"Lung Transplant Service, Alfred Health and Monash University, Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda A.","family":"Paraskeva","sequence":"additional","affiliation":[{"name":"Lung Transplant Service, Alfred Health and Monash University, Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldho","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton Y.","family":"Peleg","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory I.","family":"Snell","sequence":"additional","affiliation":[{"name":"Lung Transplant Service, Alfred Health and Monash University, Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20231107","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1111\/j.1600-6143.2011.03663.x","article-title":"Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome.","volume":"11","author":"Paraskeva","year":"2011","journal-title":"Am J Transplant"},{"key":"R2-20231107","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1164\/rccm.200911-1786OC","article-title":"Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation.","volume":"181","author":"Snyder","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"R3-20231107","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1128\/JVI.77.9.5226-5240.2003","article-title":"Ex vivo profiling of CD8+\u2212T cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers.","volume":"77","author":"Elkington","year":"2003","journal-title":"J Virol"},{"key":"R4-20231107","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1097\/01.TP.0000069234.04901.A3","article-title":"Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation.","volume":"75","author":"Westall","year":"2003","journal-title":"Transplantation"},{"key":"R5-20231107","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1600-6143.2005.01212.x","article-title":"CMV-specific CD8 T-cell dynamics in the blood and the lung allograft reflect viral reactivation following lung transplantation.","volume":"6","author":"Westall","year":"2006","journal-title":"Am J Transplant"},{"key":"R6-20231107","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/j.1600-6143.2008.02294.x","article-title":"Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T cell immunity.","volume":"8","author":"Westall","year":"2008","journal-title":"Am J Transplant"},{"key":"R7-20231107","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1600-6143.2010.03405.x","article-title":"Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis.","volume":"11","author":"Snyder","year":"2011","journal-title":"Am J Transplant"},{"key":"R8-20231107","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1164\/rccm.201504-0733OC","article-title":"Polyfunctional T cell signatures to predict protection from cytomegalovirus after lung transplantation.","volume":"193","author":"Snyder","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"R9-20231107","doi-asserted-by":"crossref","first-page":"e0135972","DOI":"10.1371\/journal.pone.0135972","article-title":"The presence of HLA-E-restricted, CMV-specific CD8+ T cells in the blood of lung transplant recipients correlates with chronic allograft rejection.","volume":"10","author":"Sullivan","year":"2015","journal-title":"PLoS One"},{"key":"R10-20231107","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4049\/jimmunol.1501589","article-title":"IL-12-dependent cytomegalovirus-specific CD4+ T cell proliferation, T-bet induction, and effector multifunction during primary infection are key determinants for early immune control.","volume":"196","author":"Popescu","year":"2016","journal-title":"J Immunol"},{"key":"R11-20231107","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/infdis\/jir624","article-title":"Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients.","volume":"204","author":"Pipeling","year":"2011","journal-title":"J Infect Dis"},{"key":"R12-20231107","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1399-3062.2006.00199.x","article-title":"Ex vivo monitoring of human cytomegalovirus-specific CD8+ T cell responses using QuantiFERON-CMV.","volume":"9","author":"Walker","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"R13-20231107","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/cid\/cis993","article-title":"Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multi-center cohort study.","volume":"56","author":"Manuel","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R14-20231107","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1600-6143.2009.02618.x","article-title":"Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients.","volume":"9","author":"Kumar","year":"2009","journal-title":"Am J Transplant"},{"key":"R15-20231107","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/TP.0b013e31823c1cd4","article-title":"Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia.","volume":"93","author":"Lisboa","year":"2012","journal-title":"Transplantation"},{"key":"R16-20231107","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/ajt.14347","article-title":"An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation.","volume":"17","author":"Kumar","year":"2017","journal-title":"Am J Transplant"},{"key":"R17-20231107","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials.","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R18-20231107","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.healun.2007.10.017","article-title":"Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection.","volume":"26","author":"Stewart","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"R19-20231107","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.healun.2013.10.022","article-title":"A new classification system for chronic lung allograft dysfunction.","volume":"33","author":"Verleden","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"R20-20231107","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/01.tp.0000209439.27719.ed","article-title":"Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.","volume":"81","author":"Ruttmann","year":"2006","journal-title":"Transplantation"},{"key":"R21-20231107","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/TP.0b013e3181ea3955","article-title":"An international survey of cytomegalovirus management practices in lung transplantation.","volume":"90","author":"Zuk","year":"2010","journal-title":"Transplantation"},{"key":"R22-20231107","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1056\/NEJM199905133401903","article-title":"Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.","volume":"340","author":"Lowance","year":"1999","journal-title":"N Engl J Med"},{"key":"R23-20231107","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/j.1600-6143.2004.00571.x","article-title":"Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin valganciclovir is safe and effective for prevention of CMV infection following lung transplantation.","volume":"4","author":"Zamora","year":"2004","journal-title":"Am J Transplant"},{"key":"R24-20231107","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/0003-4819-152-12-201006150-00003","article-title":"Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized controlled trial.","volume":"152","author":"Palmer","year":"2010","journal-title":"Ann Intern Med"},{"key":"R25-20231107","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","article-title":"Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation.","volume":"96","author":"Kotton","year":"2013","journal-title":"Transplantation"},{"key":"R26-20231107","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.0105-2896.2005.00271.x","article-title":"Human immunosenescence: is it infectious?","volume":"205","author":"Pawelec","year":"2005","journal-title":"Immunol Rev"},{"key":"R27-20231107","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/TP.0b013e3181cee42f","article-title":"International consensus guidelines on the management of cytomegalovirus in solid organ transplantation.","volume":"89","author":"Kotton","year":"2010","journal-title":"Transplantation"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007890-201905000-00029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T21:12:31Z","timestamp":1699391551000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201905000-00029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000002454","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}